Cleary Gottlieb representa a algunas de las más grandes empresas farmacéuticas y biotecnológicas del mundo en importantes operaciones empresariales, así como en materias relacionadas a la libre competencia, sectores regulados, arbitraje y derecho procesal civil. Cleary Gottlieb también asesora a instituciones financieras especializadas en operaciones en estos sectores.

A través de las 12 oficinas internacionales del despacho, nuestros abogados trabajan con frecuencia en operaciones que afectan a varias jurisdicciones en todo tipo de operaciones empresariales, como, por ejemplo, operaciones de concentración, adquisiciones, joint ventures, y demás transacciones que permiten a nuestros clientes alcanzar sus objetivos.

Entre los asuntos más importantes de esta práctica se incluyen:

• Regular EC law counsel to Merck & Co. on a cutting-edge issues, including in precedent-setting European Court of Justice win regarding the interpretation of the World Trade Organization’s Agreement on Trade Related Aspects of Intellectual Property Rights and in antitrust challenges by generic companies.
  
  
• Antitrust counsel to GlaxoSmithKline in connection with numerous transactions, including its recent $15 billion bid to acquire Pfizer’s consumer health care business.
  
  
• Counsel to Boehringer Ingelheim in precedent-setting European Court of Justice win regarding the scope of trademark owners’ rights in relation to parallel importers that repackage pharmaceutical products.
  
  
• Regular counsel to Medtronic on a range of matters, including in its $3.9 billion Kyphon acquisition.
  
  
• Counsel to TPG, Blackstone, Goldman Sachs and KKR in $10.9 billion Biomet acquisition—one of the largest LBOs of all time.
  
  
• Antitrust counsel to Merck & Co. in its collaboration with GTx to advance research and development of selective androgen receptor modulators (SARM).
  
  
• Regular global counsel to 3M, including in the sale of its global pharmaceuticals business to three buyers.
  
  
• Counsel to GlaxoSmithKline in many litigation matters, including a class action litigation in U.S. federal court relating to allegations of patent misuse in connection with Augmentin, GSK’s drugs for treating HIV/AIDS; a U.S. class action challenging GSK’s efforts to restrict illegal export and price-fixing of its products; the simultaneous resolution of a number of pending actions related to Wellbutrin XL; as well as on antitrust issues arising from the settlement of a patent litigation involving Paxil.
  
  
• Counsel to GlaxoSmithKline and its U.S. subsidiary SmithKline Beecham in the $1.65 billion acquisition of Reliant Pharmaceuticals, as well as to GSK in its acquisitions of Domantis Limited, Praecis Pharmaceuticals, CNS, ID Biomedical Corporation and Corixa.
  
  
• Counsel to Lundbeck in connection with the distribution of pharmaceutical products in Europe.